MedTrace Logo

Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

NCT03710824 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2024-07-31

Study results available
· View outcomes & findings →

Summary

Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.

Conditions

Interventions

DRUG

Nintedanib

diagnosed IPF patients initiating treatment with nintedanib

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2023-02-22
Completion
2023-02-22
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03710824 on ClinicalTrials.gov